Replies to post #250359 on Innovation Pharmaceuticals Inc (IPIX)

[MackG]

Thanks, DaubersUP.
"Innovation Pharma is separated from the pack in a number of ways, including being Phase 3-ready and hitting the primary endpoint in the Phase 2 study by demonstrating that their oral rinse formulation was beneficial in preventing the onset of SOM in addition to key secondary endpoints, namely reducing the duration of SOM when it did develop. Most other pharmas developing drugs are focused on reducing duration, not prevention." Like!

[TheDane]

Nice! Thanks!

[williamssc]

Most other pharmas developing drugs are focused on reducing duration, not prevention.

Innovation also reported Brilacidin-OM patients feeling better (less swollen, less burning sensation) compared to those in the placebo arm, which was underscored by the fact that was not a single unplanned office visit, emergency room visits or hospital admission by a patient in the treatment arm, compared to four in the placebo group.

While the company continues to cull the data and prepares for an end of phase 2 meeting with the FDA, it hasn’t discussed the next potential step forward. Considering the efficacy in HNC patients on high doses of cisplatin, this would seem like a logical pathway to structure a Phase 3 study to increase the odds of success and attracting a high-profile partner with the end-game being the first to market.

Great times ahead for share holders.

[LilyGDog]

Great release and read. Thanks DaubersUP.

Go Leo & IPIX!

Great Article on OM

http://www.baystreet.ca/articles/stockstowatch/38594/Taking-a-Page-from-Mercks-Gardasil-and-Glaxos-Requip-These-Small-Companies-Look-to-Cement-Riches-for-Shareholders-in-New-Category-of-Oral-Mucositis
© 2018 InvestorsHub.com, Inc.

[CallMeCrazy]

Great article. A few insightful tidbits:

IPIX showed that Brilacidin-OM reduced the risk of the incidence of SOM in patients receiving aggressive chemotherapy (high doses of cisplatin) by as much as 80.3% compared to placebo. Given the trend in HNC treatment programs moving towards higher dosing regimens, this latest piece of data is particularly important towards the goal of one day seeing Brilacidin-OM as an integral part of every HNC treatment program.

Considering the efficacy in HNC patients on high doses of cisplatin, this would seem like a logical pathway to structure a Phase 3 study to increase the odds of success and attracting a high-profile partner with the end-game being the first to market.

... the aggregate of prevention and cutting SOM duration from 5.5 days to under 1 is nothing shy of impressive and essentially unparalleled by competitors.

The data is there for IPIX and the company says it wants to formulate its product in a sachet format (like a sugar packet) for easy administration away from a medical setting, which is ideal.

Thanks for sharing.

http://www.baystreet.ca/articles/stockstowatch/38594/Taking-a-Page-from-Mercks-Gardasil-and-Glaxos-Requip-These-Small-Companies-Look-to-Cement-Riches-for-Shareholders-in-New-Category-of-Oral-Mucositis

[Blue Fin]

DU, Good to see IPIX there and comparisons.